Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CMV-TCR-T cells (Chinese PLA General Hospital)
- Development stage
- Unknown
- Lead developer
- Chinese PLA General Hospital
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CMV-TCR-T cells is an investigational T cell receptor (TCR) engineered T cell therapy developed by the Chinese PLA General Hospital. It is designed for the treatment of cytomegalovirus (CMV) infection and reactivation in patients following allogeneic hematopoietic stem cell transplantation (HSCT), particularly in the context of haploidentical peripheral blood stem cell transplantation. The therapy involves the adoptive transfer of donor-derived T cells that have been genetically modified to express TCRs specific for CMV antigens. These engineered cells are intended to recognize and eliminate CMV-infected cells, providing a pre-emptive or first-line treatment option to restore anti-viral immunity and prevent complications associated with CMV reactivation in immunocompromised post-transplant patients.
- Other names
- donor-derived CMV-TCR-T cellsCMV-specific TCR-engineered T cellsCMV-TCR-T cells
02
Targets
Cytomegalovirus phosphoprotein 65 (pp65) peptide-Human Leukocyte Antigen A*11:01 complexpp65/HLA-A*02:01 (CMV pp65 peptide-HLA-A*02:01 complex)CMV pp65/HLA-A*24:02 (CMV pp65 peptide-HLA-A*24:02 complex)
Beyond the preview
Go deeper on CMV-TCR-T cells (Chinese PLA General Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CMV-TCR-T cells (Chinese PLA General Hospital).